Business
Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced that the Company’s management team will present at the 44th Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 12-15, 2026. The management team will also participate in one-on-on
About this update from Vera Therapeutics, Inc.
[{"type":"image","alt":"Vera Therapeutics","displaySize":"","headline":null,"caption":"Vera Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/72a8e9e8ecc86f0d9732b38c0cd327c5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6..aCv7B4Q_6wAcqlLyx_A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/72a8e9e8ecc86f0d9732b38c0cd327c5","width":300,"height":300}},"lazy":false},{"type":"text","content":"BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced that the Company’s management team will present at the 44th Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 12-15, 2026. The management team will also participate in one-on-one investor meetings.","length":520,"tagName":"p"},{"type":"text","content":"Presentation Details:Date: Tuesday, January 13, 2026Time: 2:15 PM PSTWebcast: https://jpmorgan.metameetings.net/events/healthcare26/sessions/317196-vera-therapeutics-inc/webcast?gpu_only=true&kiosk=true","length":209,"tagName":"p"},{"type":"text","content":"A replay of the event will be available for 90 days and can be accessed by visiting the “Investor Calendar” section of the Vera Therapeutics website.","length":149,"tagName":"p"},{"type":"text","content":"About Vera TherapeuticsVera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera Therapeutics’ mission is to advance treatments that target the source of disease in order to change the standard of care for patients. Vera Therapeutics’ lead product candidate is atacicept, a fusion protein self-administered at home as a subcutaneous once weekly injection that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including immunoglobulin A nephropathy (IgAN) and lupus nephritis. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies by ata...